Saffron Therapy for Ulcerative Colitis via Microbiota Balance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for safe and effective complementary treatments for inflammatory bowel disease (IBD), particularly ulcerative colitis, as current immunosuppressive anti-inflammatory agents have adverse effects and there is a lack of detailed mechanistic studies on herbal agents like saffron for intestinal inflammation and gut microbiota modulation.
Innovation Solution
Saffron is administered as an active ingredient to upregulate HO-1/GPx2, regulate immune cells, and maintain microbiota homeostasis, thereby improving colon gross and histological features, reducing pro-inflammatory markers, and altering microbial taxa.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If immunosuppressive anti-inflammatory agents are used to treat IBD, then inflammation is suppressed, but adverse effects and intolerances increase
Solution Approach 1:
The patent employs saffron, a natural plant-based substance, as a safer alternative to conventional immunosuppressive drugs. Saffron provides anti-inflammatory effects through multiple mechanisms (upregulating HO-1/GPx2, regulating immune cells, maintaining microbiota homeostasis) without the severe adverse effects associated with traditional therapies, effectively replacing harmful long-term immunosuppressants with a safer natural agent.
2Object-generated harmful factors
If herbal agents like saffron are used for treatment, then safety improves, but lack of mechanistic studies and dosing data limits efficacy
Solution Approach 1:
The patent comprehensively characterizes saffron's mechanisms of action through multiple lines of evidence: upregulation of HO-1/GPx2 antioxidant pathway, regulation of immune cell profiles (increasing anti-inflammatory M2 macrophages and regulatory T cells), and maintenance of gut microbiota homeostasis. This detailed mechanistic understanding provides the missing information needed to translate herbal therapy into evidence-based medicine.
3Reliability
If current IBD therapies are continued, then disease control is maintained, but patients lose response and experience drug-induced adverse events
Solution Approach 1:
The patent introduces saffron as a therapeutic agent with different mechanistic parameters compared to conventional IBD treatments. Instead of relying on单一 immunosuppression pathways, saffron acts through multiple parameters simultaneously: antioxidant defense (HO-1/GPx2 upregulation), immune cell differentiation (M1 to M2 macrophage conversion), and microbiota modulation, providing a multi-parameter approach that may overcome treatment resistance.
Data Source
AI summary
A method for treating or mitigating Inflammatory bowel disease (IBD), particularly ulcerative colitis, including administering an effective amount of saffron to a subject in need thereof. A novel treatment in IBD, particularly ulcerative colitis, is thus provided.